# KRYSTAL-12 plain language summary: adagrasib for non-small-cell lung cancer with KRAS G12C mutations

Source: https://onco.cc/key-papers/paper-krystal-12-plain-language-summary-future-oncol-2026/  
OnCo record `paper-krystal-12-plain-language-summary-future-oncol-2026` (Key paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A plain-language account of the KRYSTAL-12 trial, written for patients and carers, explaining how adagrasib compared with docetaxel chemotherapy in previously treated KRAS G12C lung cancer.

## Summary

Plain language summary of the phase 3 KRYSTAL-12 trial, which randomised previously treated patients with KRAS G12C-mutated non-small-cell lung cancer to the KRAS G12C inhibitor adagrasib or docetaxel. Written by the trial investigators for a non-specialist reader, it restates the design, the progression-free survival result and the side-effect profile of the primary publication.

Europe PMC indexes no abstract for this article, so OnCo carries no figures from it; the trial's own record holds the primary result from the pivotal publication.

## Fields

- Kind: Key paper
- Last checked: 2026-09-21
- Journal: Future Oncology
- Year: 2026
- DOI: 10.1080/14796694.2026.2719409
- Authors: Barlesi F, Yao W, Duruisseaux M, et al.
- Findings: Restates the KRYSTAL-12 result in plain language for patients: adagrasib compared with docetaxel after prior treatment for KRAS G12C lung cancer.
- What it means: Useful for a patient offered adagrasib after chemotherapy or immunotherapy who wants the trial explained without jargon. It adds no new data; the primary KRYSTAL-12 publication and the trial page remain the reference for the numbers.
- Caveats: A plain language summary of a published trial, not a new analysis; it reports no results beyond the primary publication.; No abstract is indexed on Europe PMC, so no figures have been transcribed here.

## Sources

- Future Oncol 2026: https://doi.org/10.1080/14796694.2026.2719409
- PubMed: https://pubmed.ncbi.nlm.nih.gov/42745627/
- ClinicalTrials.gov NCT04685135: https://clinicaltrials.gov/study/NCT04685135

## Connected records

- cancers: [KRAS G12C-mutant non-small-cell lung cancer](https://onco.cc/cancers/kras-g12c-nsclc/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- targets: [KRAS](https://onco.cc/targets/kras/)
- drugs: [Adagrasib](https://onco.cc/drugs/adagrasib/)
- companies: [Bristol Myers Squibb](https://onco.cc/companies/bms/)
- trials: [KRYSTAL-12](https://onco.cc/trials/krystal-12/)
- people: [Fabrice Barlesi](https://onco.cc/people/fabrice-barlesi/), [Martin Reck](https://onco.cc/people/martin-reck/), [Shun Lu](https://onco.cc/people/lu-shun/), [Tony S. K. Mok](https://onco.cc/people/tony-mok/)
- journals: [Future oncology](https://onco.cc/journals/future-oncology/)

---
JSON: https://onco.cc/api/v1/entities/paper-krystal-12-plain-language-summary-future-oncol-2026.json